Bausch Health Companies Inc (BHC)

Currency in USD
5.65
-0.07(-1.22%)
Closed·
5.60-0.05(-0.89%)
·
BHC is included in our AI-picked strategies. See how they work
Fair Value
Day's Range
5.385.72
52 wk Range
4.418.69
Key Statistics
Prev. Close
5.72
Open
5.72
Day's Range
5.38-5.72
52 wk Range
4.41-8.69
Volume
3.15M
Average Volume (3m)
1.96M
1-Year Change
17.3585%
Book Value / Share
-1.5
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BHC Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
7.57
Upside
+34.01%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell

Analyst Ratings

1 Buy
8 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 7.57
(+34.01% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
RBC Capital
Hold9.00+59.29%10.00Maintain27/04/2026
Barclays
Hold7.00+23.89%8.00Maintain25/02/2026
Raymond James
Hold---Maintain26/01/2026
Barclays
Hold8.00+41.59%-New Coverage09/12/2025
Raymond James
Hold8.00+41.59%9.00Maintain05/05/2025

Bausch Health Companies Inc SWOT Analysis


Financial Resilience
Bausch Health's Q3 2024 results showcase robust growth, with revenues of $2.51 billion marking a 12% year-over-year increase and 9% organic growth
Debt Dilemma
Explore the complexities of Bausch Health's $21.5 billion debt burden and its impact on strategic initiatives, including potential bankruptcy concerns
Strategic Crossroads
Delve into Bausch Health's plans for asset separation, particularly the Bausch+Lomb division, and how debt issues may affect these crucial moves
Market Sentiment
Analysts offer mixed views, with price targets ranging from $8 to $11, reflecting the tension between strong performance and financial challenges
Read full SWOT analysis

Bausch Health Companies Inc Earnings Call Summary for Q1/2026

  • Bausch Health Q1 2026 EPS of $0.78 beat estimates by 14.71%; revenue of $2.52B exceeded forecasts by 4.13%, marking 12th straight growth quarter.
  • Adjusted EBITDA surged 27% YoY to $837M; adjusted gross margin improved 100 bps to 70.9%, driven by strong Salix and Solta segment performance.
  • Company projects Q2-Q4 EPS range of $1.02-$1.42; plans to launch 30+ new products in EMEA and expand Latin American presence to sustain growth.
  • Stock declined 0.71% to $5.63 in after-hours trading despite earnings beat, reflecting broader market pressures rather than company-specific concerns.
  • CEO Papa cited operational excellence; CFO Herendeen noted litigation settlements enhance financial flexibility for strategic growth investments.
Last Updated: 29/04/2026, 23:06
Read Full Transcript

Earnings

Latest Release
29/04/2026
EPS / Forecast
0.78 / 0.68
Revenue / Forecast
2.52B / 2.42B
EPS Revisions
Last 90 days

Compare BHC to Peers and Sector

Metrics to compare
BHC
Peers
Sector
Relationship
P/E Ratio
−1.7x19.2x−0.5x
PEG Ratio
0.000.110.00
Price/Book
−3.8x1.4x2.6x
Price / LTM Sales
0.2x2.0x3.2x
Upside (Analyst Target)
39.9%69.5%47.8%
Fair Value Upside
Unlock24.1%6.7%Unlock

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. The company sells its products in the United States, China, Canada, Poland, Mexico, France, South Korea, Russia, Japan, Germany, the United Kingdom, Spain, Italy, and internationally. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Employees
20300

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
39.96M10.70%228.56M
Other Institutional Investors
226.47M60.64%1.30B
Public Companies & Retail Investors
107.03M28.66%612.23M
Total
373.46M100.00%2.14B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Paulson & Co. Inc.19.62%73,255,869419,024
GoldenTree Asset Management LP9.28%34,665,731198,288

People Also Watch

17.27
PENN
-1.09%
20.03
OPCH
-1.48%
46.92
FE
-1.26%
48.04
CNA
-0.39%

FAQ

What Is the Bausch Health (NYSE: BHC) Share Price Today?

The Bausch Health stock price today is 5.65 USD.

What Stock Exchange Does Bausch Health (BHC) Trade On?

Bausch Health is listed and trades on the New York Stock Exchange.

What Is the Ticker (Stock Symbol) for Bausch Health?

The stock symbol (also called a 'ticker') for Bausch Health is "BHC."

What Is the Current Bausch Health Market Capitalisation?

As of today, Bausch Health (NYSE: BHC) market cap is 2.11B USD.

What Is Bausch Health's (BHC) Earnings Per Share (TTM)?

The Bausch Health EPS is currently -3.31 (Trailing Twelve Months).

When Is the Next Bausch Health Earnings Date?

Bausch Health's next earnings report will be released on 05/08/2026.

Is BHC a Buy or Sell From a Technical Analyst Perspective?

Based on today's Bausch Health moving averages and other technical indicators, the daily buy/sell signal for BHC stock is Strong Sell.

How Many Times Has Bausch Health Stock Split?

Bausch Health has split 3 times. (See the BHC stock split history page for full effective split date and price information.)

How Many Employees Does Bausch Health Have?

Bausch Health has 20300 employees, based on their latest Companies House report.

What is the current trading status of Bausch Health (NYSE: BHC)?

As of 02/05/2026, Bausch Health (BHC) is trading at a share price of 5.65 USD, with a previous close of 5.72 USD. The stock has fluctuated within a day range of 5.38 USD to 5.72 USD, while its 52-week range spans from 4.41 USD to 8.69 USD.

What Is Bausch Health (BHC) Price Target According to Analysts?

The average 12-month price target for Bausch Health is 7.57 USD, with a high estimate of 9 USD and a low estimate of 6 USD. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Neutral. The stock has an +34.01% Upside potential.

What Is the BHC Premarket Price?

BHC's last pre-market stock price is 5.75 USD. The pre-market share volume is 5,090.00, and the stock has decreased by 0.03, or 0.52%.

What Is the BHC After Hours Price?

BHC's last after hours stock price is 5.60 USD, the stock has decreased by -0.05, or -0.89%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.